MD3377485T2 - Formă în stare solidă a unor compuși de piridină pladienolidă și metode de utilizare - Google Patents
Formă în stare solidă a unor compuși de piridină pladienolidă și metode de utilizare Download PDFInfo
- Publication number
- MD3377485T2 MD3377485T2 MDE20180923T MDE20180923T MD3377485T2 MD 3377485 T2 MD3377485 T2 MD 3377485T2 MD E20180923 T MDE20180923 T MD E20180923T MD E20180923 T MDE20180923 T MD E20180923T MD 3377485 T2 MD3377485 T2 MD 3377485T2
- Authority
- MD
- Moldova
- Prior art keywords
- pyridine
- compounds
- methods
- pladienide
- solid form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Prezenta descriere prevede o nouă formă solidă a compuşilor de piridină pladienolidă, compoziţii cuprinzând cel puţin o astfel de formă de stare solidă şi metode de preparare şi utilizare a acestora. Noua formă în stare solidă a compuşilor de piridină pladienolidă poate fi utilă în tratamentul cancerului, cum ar fi, de exemplu, cancerele în care sunt cunoscuţi ca fiind utili, agenţii care vizează spliceozomul şi mutaţiile din acesta.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257088P | 2015-11-18 | 2015-11-18 | |
| PCT/US2016/062525 WO2017087667A1 (en) | 2015-11-18 | 2016-11-17 | A solid state form of pladienolide pyridine compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD3377485T2 true MD3377485T2 (ro) | 2020-02-29 |
Family
ID=57472076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20180923T MD3377485T2 (ro) | 2015-11-18 | 2016-11-17 | Formă în stare solidă a unor compuși de piridină pladienolidă și metode de utilizare |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10745387B2 (ro) |
| EP (1) | EP3377485B1 (ro) |
| JP (2) | JP6312282B2 (ro) |
| KR (1) | KR20180083376A (ro) |
| CN (1) | CN108473479B (ro) |
| AU (2) | AU2016357433B2 (ro) |
| BR (1) | BR112018009995B1 (ro) |
| CA (1) | CA3004623C (ro) |
| ES (1) | ES2757174T3 (ro) |
| IL (1) | IL259198B2 (ro) |
| MD (1) | MD3377485T2 (ro) |
| MX (2) | MX379655B (ro) |
| RU (2) | RU2021102393A (ro) |
| SG (2) | SG10201913045PA (ro) |
| WO (1) | WO2017087667A1 (ro) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200242A1 (ar) * | 2018-04-09 | 2020-09-29 | Eisai R&D Man Co Ltd | مركبات البلاديينوليد واستخداماتها |
| PE20212329A1 (es) | 2018-04-12 | 2021-12-14 | Eisai Randd Man Co Ltd | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cancer |
| US11998544B2 (en) * | 2018-06-01 | 2024-06-04 | Eisai R&D Management Co., Ltd. | Methods of using splicing modulators |
| EP4069255B1 (en) * | 2019-12-04 | 2025-10-01 | University of Massachusetts | Identifying non-productive splice sites |
| BR112022024833A2 (pt) * | 2020-06-05 | 2023-02-14 | Eisai R&D Man Co Ltd | Conjugados anticorpo anti-bcma-fármaco e métodos de uso |
| CA3199753A1 (en) | 2020-11-04 | 2022-05-12 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI312681B (en) | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
| TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| CN1671856B (zh) | 2002-07-31 | 2010-05-12 | 卫材R&D管理株式会社 | 生理活性物质 |
| WO2004011459A1 (ja) | 2002-07-31 | 2004-02-05 | Mercian Corporation | 新規生理活性物質 |
| WO2004037212A2 (en) | 2002-10-24 | 2004-05-06 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| CA2507641A1 (en) | 2002-11-29 | 2004-06-17 | Mercian Corporation | Method of producing macrolide compound |
| CN1886505A (zh) | 2003-11-27 | 2006-12-27 | 美露香株式会社 | 参与大环内酯类化合物的羟化作用的dna |
| ATE466937T1 (de) | 2003-11-28 | 2010-05-15 | Kanagawa Kagaku Gijutsu Akad | Verfahren zum nachweis von leberkrebs, diagnostikum für leberkrebs sowie heilmittel gegen krebs |
| WO2006003706A1 (ja) | 2004-07-02 | 2006-01-12 | Plus One Techno & Co., Ltd. | 組み合わせ計量技術 |
| CN1977046A (zh) | 2004-07-20 | 2007-06-06 | 卫材R&D管理有限公司 | 编码参与普拉地内酯生物合成的多肽的dna |
| TW200716744A (en) | 2005-05-26 | 2007-05-01 | Eisai R&D Man Co Ltd | Genetically modified microorganism and process for production of macrolide compound using the microorganism |
| JPWO2007043621A1 (ja) | 2005-10-13 | 2009-04-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラジエノライドｂ及びプラジエノライドｄの全合成方法 |
| JPWO2008111464A1 (ja) | 2007-03-05 | 2010-06-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スプライシング異常を指標とする抗ガン剤の作用検定方法 |
| US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
| LT3143016T (lt) | 2014-05-15 | 2019-06-10 | Eisai R&D Management Co., Ltd. | Pladienolido piridino junginiai ir panaudojimo būdai |
-
2016
- 2016-11-17 AU AU2016357433A patent/AU2016357433B2/en active Active
- 2016-11-17 KR KR1020187016598A patent/KR20180083376A/ko active Pending
- 2016-11-17 CA CA3004623A patent/CA3004623C/en active Active
- 2016-11-17 CN CN201680067749.5A patent/CN108473479B/zh active Active
- 2016-11-17 WO PCT/US2016/062525 patent/WO2017087667A1/en not_active Ceased
- 2016-11-17 RU RU2021102393A patent/RU2021102393A/ru unknown
- 2016-11-17 MX MX2018006155A patent/MX379655B/es unknown
- 2016-11-17 MD MDE20180923T patent/MD3377485T2/ro unknown
- 2016-11-17 ES ES16805664T patent/ES2757174T3/es active Active
- 2016-11-17 JP JP2017528992A patent/JP6312282B2/ja active Active
- 2016-11-17 RU RU2018121610A patent/RU2743349C2/ru active
- 2016-11-17 US US15/529,798 patent/US10745387B2/en active Active
- 2016-11-17 BR BR112018009995-3A patent/BR112018009995B1/pt active IP Right Grant
- 2016-11-17 SG SG10201913045PA patent/SG10201913045PA/en unknown
- 2016-11-17 MX MX2021001441A patent/MX392475B/es unknown
- 2016-11-17 EP EP16805664.6A patent/EP3377485B1/en active Active
- 2016-11-17 SG SG11201803519YA patent/SG11201803519YA/en unknown
- 2016-11-17 IL IL259198A patent/IL259198B2/en unknown
-
2018
- 2018-03-16 JP JP2018049098A patent/JP6353620B1/ja active Active
-
2020
- 2020-07-17 US US16/932,627 patent/US20200361915A1/en not_active Abandoned
-
2021
- 2021-02-15 AU AU2021200974A patent/AU2021200974B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD3377485T2 (ro) | Formă în stare solidă a unor compuși de piridină pladienolidă și metode de utilizare | |
| CY1121517T1 (el) | Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib | |
| ZA201708692B (en) | Antibacterial compounds | |
| PH12017501483A1 (en) | Bicyclic heterocycles as fgfr4 inhibitors | |
| WO2018112365A3 (en) | Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii | |
| EP4620519A3 (en) | Methods and compositions relating to chondrisomes from blood products | |
| MX2017004579A (es) | Estructuras fibrosas solubles y metodos para fabricarlas. | |
| SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| MX2016016143A (es) | Compuestos de [1,2,4]triazol sustituido. | |
| NZ730803A (en) | Methods for the preparation of ribosides | |
| MX2015010125A (es) | Derivados de piridazinona-amidas. | |
| MX382600B (es) | Forma cristalina de base libre de lorlatinib. | |
| MX373324B (es) | Compuestos piridínicos de pladienolida y métodos de uso. | |
| GEP201706760B (en) | Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same | |
| WO2019023315A3 (en) | Rac inhibitors | |
| MY203626A (en) | Compositions and methods for inhibiting the biological activity of soluble biomolecules | |
| NO20180002A1 (en) | Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors | |
| MX384259B (es) | Composiciones y metodos para tratamiento de crecimiento celular anormal. | |
| PH12017501147A1 (en) | Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs | |
| NZ778505A (en) | Crystalline form of lorlatinib free base | |
| HK1246796A1 (en) | Bicyclic heterocycles as fgfr4 inhibitors | |
| HK1254258A1 (zh) | 使用阿吡莫德治疗癌症的方法 | |
| HK1230956A1 (en) | Compositions and methods for treatment of abnormal cell growth |